AbbVie commits £120 million to expand its Oxford R&D center, targeting immunology, neuroscience, and oncology pipelines. This move reinforces commitment to UK-based innovation hubs. The investment signals continued confidence in the UK pharmaceutical sector despite broader economic headwinds. It highlights ongoing demand for specialized R&D infrastructure in therapeutic areas with high unmet medical needs. For AbbVie, this enhances operational capacity for late-stage drug discovery and collaboration with academic partners. Capital expenditure increases may pressure short-term margins while supporting long-term pipeline growth.
3 articles
AbbVie announced a £120 million investment to expand its Oxford R&D facility, enhancing capabilities in immunology, neuroscience, and oncology. The expansion supports new disease target research and s
A U.S. House committee launched an investigation into Merck and AbbVie over clinical trials in China, citing national security and ethical risks. Lawmakers require details on trial sites by July 17 am
AbbVie reported better-than-expected quarterly revenue driven by growth in Skyrizi and Rinvoq, offsetting declines in Humira sales. The company raised its full-year earnings forecast while noting stro
ChemBrief